Continuing medical educationUpdate on morphea: Part I. Epidemiology, clinical presentation, and pathogenesis
Section snippets
Epidemiology
Key points The incidence of morphea is 0.4 to 2.7 per 100,000 people Morphea is more common in whites Morphea is more common in females The prevalence of morphea is equal in adults and children
Morphea is a rare fibrosing disorder of the skin and underlying tissues. Epidemiologic studies have reported its incidence as 0.4 to 2.7 per 100,000 people.1, 2 A female predominance of 2.4 to 4.2:1 has been reported.3, 4 Several retrospective reviews have been published in the last 5 years with similar epidemiologic
Classification
Key points Morphea classification systems are based on clinical phenotype
Morphea is classified based on clinical presentations. The landmark article of morphea classification was published in 1995 by Peterson et al7 (Table I). Peterson et al7 recommended five subclassifications of morphea: plaque (including morphea en plaque [Fig 1], guttate [Fig 2], atrophoderma of Pasini and Pierini, keloidal, and lichen sclerosis et atrophicus); generalized (involving more than 2 body areas [Fig 3]); bullous; linear
Clinical presentation
Key points Early lesions of morphea present as erythematous to dusky violaceous patches and plaques that resolve into sclerotic, hairless, anhidrotic plaques with varying amounts of postinflammatory hyperpigmentation The most common clinical subsets of morphea are plaque, linear, general, and pansclerotic Plaque morphea is the most common presentation in adults Linear morphea is the most common presentation in children and often presents with fibrosis of underlying tissues, resulting in additional morbidity
Clinical differentiation from systemic sclerosis
Key points The presence of Raynaud phenomenon, nailfold capillary changes, and sclerodactyly are the earliest findings in patients with systemic sclerosis Primary Raynaud phenomenon is not uncommon in the general population Secondary Raynaud phenomenon should be suspected when onset is after 30 years of age, there are accompanying nailfold capillary changes, or there is digital necrosis
When examining a patient with “scleroderma,” differentiating morphea from systemic sclerosis is the physician’s paramount
Histology
Key points Morphea and systemic sclerosis cannot be differentiated by histopathologic examination Early morphea and systemic sclerosis lesions have lymphocytic perivascular infiltration in the reticular dermis and swollen endothelial cells Late morphea and systemic sclerosis lesions are characterized by thickened collagen bundles infiltrating the entire dermis and extending into the subcutaneous fat Loss of eccrine glands and blood vessels and “fat trapping” are common histologic findings in late morphea and
Systemic manifestations
Key points Extracutaneous manifestations in morphea are not rare The most common extracutanous manifestation is arthralgia Central nervous system fibrosis is most common in those children with head and neck involvement Children with head and neck morphea should have regular ophthalmologic examinations to monitor for asymptomatic involvement that may lead to irreversible damage (level III evidence) Patients with morphea are likely to have a family history of autoimmunity
Extracutaneous manifestations of morphea
Pathogenesis
Key points The underlying etiology of morphea is unknown Development of morphea likely requires an underlying predisposition and an environmental encounter Proposed environmental factors include trauma, medications, and infections Proposed host factors include autoimmunity and microchimerism
The underlying etiology of morphea remains elusive. The development of morphea is likely a multifactorial process. The following factors have all been associated with the formation of morphea: trauma/radiation,
Molecular pathogenesis
Key points Morphea lesions may be initiated by vascular injury The vascular injury increases expression of adhesion molecules, which recruit inflammatory cells The recruited inflammatory cells increase production of profibrotic cytokines, such as transforming growth factor–beta The profibrotic cytokines increase collagen production and decrease collagen destruction, resulting in an overabundance of collagen deposition
Both morphea and systemic sclerosis are pathologically defined by an increase in collagen
Conclusions
Morphea is a rare, clinically heterogeneous disease process defined by increased collagen deposition. Morphea is distinguished from systemic sclerosis by its lack of sclerodactyly, Raynaud phenomenon, and nailfold capillary changes. Central nervous system fibrosis most commonly affects those children with head and neck involvement. Children with head and neck morphea should have regular ophthalmologic examinations to monitor for asymptomatic involvement that may lead to irreversible damage if
References (75)
- et al.
Scleroderma in children and adolescents
Rheum Dis Clin North Am
(2002) - et al.
Pediatric morphea (localized scleroderma): review of 136 patients
J Am Acad Dermatol
(2008) - et al.
Classification of morphea (localized scleroderma)
Mayo Clin Proc
(1995) - et al.
En coup de sabre morphea and Parry-Romberg syndrome: a retrospective review of 54 patients
J Am Acad Dermatol
(2007) - et al.
Disabling pansclerotic morphea: clinical presentation in two adults
J Am Acad Dermatol
(2005) - et al.
Vitamin K1-induced localized scleroderma (morphea) with linear deposition of IgA in the basement membrane zone
J Am Acad Dermatol
(1998) - et al.
Localized scleroderma in breast cancer patients treated with supervoltage external beam radiation: radiation port scleroderma
J Am Acad Dermatol
(1996) - et al.
Drug-induced morphea: report of a case induced by balicatib and review of the literature
J Am Acad Dermatol
(2008) - et al.
Absence of Borrelia burgdorferi in patients with localized scleroderma (morphea)
J Am Acad Dermatol
(1995) - et al.
Borrelia burgdorferi DNA is undetectable by polymerase chain reaction in skin lesions of morphea, scleroderma, or lichen sclerosus et atrophicus of patients from North America
J Am Acad Dermatol
(1995)
No evidence for Borrelia burgdorferi-specific DNA in lesions of localized scleroderma
J Invest Dermatol
“Borrelia-associated early-onset morphea”: a particular type of scleroderma in childhood and adolescence with high titer antinuclear antibodies? Results of a cohort analysis and presentation of three cases
J Am Acad Dermatol
Increased serum levels of soluble vascular cell adhesion molecule 1 and E-selectin in patients with localized scleroderma
J Am Acad Dermatol
Involvement of alphavbeta5 integrin in the establishment of autocrine TGF-beta signaling in dermal fibroblasts derived from localized scleroderma
J Invest Dermatol
Autoantibodies against matrix metalloproteinase-1 in patients with localized scleroderma
J Dermatol Sci
The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993
J Rheumatol
Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study
Rheumatology (Oxford)
Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases
Arch Dermatol
Localized scleroderma in adults and children. Clinical and laboratory investigations on 239 cases
Eur J Dermatol
Localized scleroderma
Curr Opin Rheumatol
Deep morphea
Semin Cutan Med Surg
Linear morphoea follows Blaschko’s lines
Br J Dermatol
Progressive facial hemiatrophy: central nervous system involvement and relationship with scleroderma en coup de sabre
J Rheumatol
Scleroderma ‘en coup de sabre’ and progressive facial hemiatrophy. Is it possible to differentiate them?
J Eur Acad Dermatol Venereol
Disabling pansclerotic morphea of childhood poses a high risk of chronic ulceration of the skin and squamous cell carcinoma
Int J Low Extrem Wounds
Lower lip squamous cell carcinoma in disabling pansclerotic morphea of childhood
Pediatr Dermatol
The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy
Ann Rheum Dis
The role of capillaroscopy in differentiation of primary and secondary Raynaud’s phenomenon in rheumatic diseases: a review of the literature and two case reports
Rheumatol Int
Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases
Arch Intern Med
Raynaud’s phenomenon and the role of capillaroscopy
Arthritis Rheum
Raynaud phenomenon and the vascular disease in scleroderma
Curr Opin Rheumatol
Neurologic manifestations of localized scleroderma: a case report and literature review
Neurology
Ocular involvement in children with localised scleroderma: a multi-centre study
Br J Ophthalmol
Juvenile linear scleroderma with unique forms of renal involvement
Pediatr Nephrol
Evaluation of heart rhythm variability and arrhythmia in children with systemic and localized scleroderma
J Rheumatol
Psychological distress in patients with morphea and eosinophilic fasciitis
Arch Dermatol
Health-related quality of life in children and adolescents with juvenile localized scleroderma
Rheumatology (Oxford)
Cited by (310)
Mass spectrometry -based proteomic analysis of the skin of patients with localized scleroderma
2024, Journal of Dermatological ScienceQuantifying outcomes of autologous fat transplantation in different facial deformities: A systemic review and meta-analysis
2023, Journal of Plastic, Reconstructive and Aesthetic SurgeryA Case of Early Morphea Mimicking Hypopigmented Mycosis Fungoides in a Pediatric Patient
2024, American Journal of DermatopathologyA Case of Morphea After COVID-19 Vaccination
2024, DermatitisAdult linear scleroderma en coup de sabre with epileptic seizure and Coats‑like response: a case report and literature review
2024, Chinese Journal of NeurologySystematic Review of Health-Related Quality of Life Impact in Juvenile Localized Scleroderma
2024, Arthritis Care and Research
Supported in part by a Merit Review Grant from the Department of Veterans Affairs Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development, and by the National Institutes of Health (grant NIH K24-AR 02207) to Dr Werth.
This article does not reflect the views of the VHA or the US Government.